C0085297||Intravenous
C0020852||immunoglobulin G
C0279033||replacement therapy
C0086418||Human
C0312586||polyclonal
C0020852||immunoglobulin G
C0020852||immunoglobulin G
C1254351||drug
C0003257||antibody deficiency
C0279033||replacement therapy
C1963758||immunomodulatory
C0282443||review
C0020852||immunoglobulin G
C0279033||replacement therapy
C0020852||immunoglobulin G
C0279033||replacement
C0020852||intravenous IgG
C0020852||intravenous IgG
C0020852||subcutaneous IgG
C0020852||subcutaneous IgG
C0020852||intravenous IgG
C0020852||subcutaneous IgG
C1254351||new product
C0020197||hyaluronidase
C0020852||subcutaneous IgG
C0020852||intravenous IgG
C0020852||intravenous IgG
C0279033||therapy
C0574032||infusions
C0020852||immunoglobulin G
C0020852||subcutaneous IgG
C0020197||Hyaluronidase
C0020852||subcutaneous IgG
C0020852||subcutaneous IgG
C0020852||intravenous IgG
C0020197||hyaluronidase
C0020852||subcutaneous IgG
C0020852||immunoglobulin G
C0237401||individuals
C0279033||therapy
C0879626||flu-like adverse effects
C0020852||intravenous IgG
C0002792||anaphylaxis
C0879626||flu-like systemic adverse effects
C0020852||subcutaneous IgG
C0020197||hyaluronidase
C0020852||subcutaneous IgG
C1457887||inflammatory symptoms
C2697750||infusion sites
C0009566||complications
C0020852||immunoglobulin G
C0279033||therapy
C0040053||thrombotic events
C0019054||hemolysis
C0022646||Renal
C0879626||adverse effects
C0020852||intravenous IgG
C0020852||immunoglobulin G
C0031831||physicians
C0279033||therapy